Global alternative asset management firm The Carlyle Group has exited its investment in India-based pharmaceuticals company Claris Lifesciences via an open market sale on the Bombay Stock Exchange. Carlyle sold approximately 6.2 million shares, representing an 11.3 percent stake in Claris, for INR1.7 billion (approximately US$27 million). Carlyle invested US$20 million in Claris in 2006 through Carlyle Asia Growth Partners III.